

Promoting Effective Drug Development Programs: Opportunities and Priorities for FDA's Office of New Drugs

November 7, 2019 9:00 AM – 5:00 PM

U.S Food and Drug Administration White Oak Campus Building 31, Room 1503 - Great Room 10903 New Hampshire Avenue Silver Spring, MD 20993

ABSTRACT

The purpose of this public meeting is to solicit from external stakeholders specific, actionable policy suggestions that could be implemented in the near-term by the review staff of the Office of New Drugs (OND) in the Center for Drug Evaluation and Research (CDER) to promote effective drug development programs without compromising our regulatory standards for assessment of safety and effectiveness.

Please note that times may vary based on participation and other logistics and are subject to change.

D - -:--------

0.45 484 0.00 484

AGENDA

8:15 AM – 9:00 AM	Registration Great Room Lobby
9:00 AM – 9:30 AM	Introductions and Opening Remarks Patrizia Cavazzoni, Deputy Director for Operations, Office of the Center Director (OCD), CDER, FDA Keith Flanagan, Director, OND Policy, OND, CDER, FDA
9:30 AM – 10:45 AM	Session 1 Public Presentations Peter Pitts, President, Center for Medicine in the Public Interest Jennifer Hamilton, Sr. Director and Head, Precision Medicine, and Maya Bermingham, VP, Public Policy & Governmental Affairs, Regeneron Pharmaceuticals Judith Prescott, Executive Director, Merck & Co., Inc. Paul Melmeyer, Director of Regulatory Affairs, Muscular Dystrophy Association Arthur Krieg, Founder and CSO, Checkmate Pharmaceuticals Tim Yu, Attending Physician, Boston Children's Hospital, and Julia Vitarello, CEO, Mila's Miracle Foundation Janice Soreth, Managing Director, Janice M Soreth MD, LLC
10:45 AM – 11:00 AM	Break

11:00 AM – 12:15 PM

Session 2 Public Presentations

Elliott Levy, SVP Global Development, Amgen

Katrin Rupalla, SVP Regulatory Affairs, MedDoc & R&D Quality, Lundbeck

Mark Stewart, VP, Science Policy, Friends of Cancer Research

Russell Reeve, Sr. Biostatistics Director, IQVIA, Inc.

Peter Schiemann, Managing Partner, Widler & Schiemann AG

Jitendra Ganju, Principal, Ganju Clinical Trials, LLC

Meg Jardine, Deputy Director of the Renal & Metabolic Division, The George Institute for

Global Health

12:15 PM - 1:15 PM

Lunch Break

1:15 PM - 2:30 PM

Session 3 Public Presentations

Ting-Chao Chou, President, PD Science, LLC

Charles Fisher, Founder and CEO, Unlearn. Al, Inc.

Andrew Emmett, FDA Liaison, Global Regulatory Policy & Intelligence, Pfizer Inc. Kelly Close, Founder and CEO, Emily Fitts, Senior Manager, Advocacy & Policy, and

Cherise Shockley, Community Manager, The diaTribe Foundation

James Love, Director, Knowledge Ecology International

Andrew Robertson, Head, Regulatory Science and Policy, Sanofi

Andrew Gustafson, Sr. Director, US Regulatory Policy and Advocacy, GlaxoSmithKline

2:30 PM - 2:45 PM

Break

2:45 PM - 4:00 PM

Session 4 Public Presentations

Frank Sasinowski, Vice Chair, EveryLife Foundation for Rare Diseases

Frederick Derosier, Executive Medical Director, Rare Disease & Pediatrics Team, Covance Inc.

Lucy Vereshchagina, VP Science and Regulatory Advocacy, PhRMA

Martin Roessner, Corporate Vice President, Biostatistics, Parexel

James Valentine, Associate, Hyman, Phelps & McNamara. P.C.

Cartier Esham, Executive VP, Emerging Companies Section, SVP, Science and

Regulatory Affairs, Biotechnology Innovation Organization

Liza O'Dowd, VP Global Regulatory Affairs, Immunology, Regulatory Policy and

Intelligence, and North American Liaison, Janssen R&D

4:00 PM - 4:15 PM

Conclusions and Closing Remarks

Keith Flanagan, Director, OND Policy, OND, CDER, FDA